Summary: Alkylating chemotherapy is the mainstay in the treatment of pediatric and adult glioblastoma despite primary and acquired resistance and scientific efforts to precisely define therapies for individual patients. A focus on non–MGMT-mediated temozolomide resistance for pediatric glioblastoma suggests options for new drug combinations. Cancer Discov; 4(10); 1120–2.
No takes yet. Share an insight, caveat, or question.
Wick et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: